Southern Cancer Center, a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.
This phase III clinical trial will look at various investigational combination therapies including an immune checkpoint inhibitor. This is an important trial to gain information on previously untreated advanced or metastatic renal cell carcinoma (RCC).
The varieties of cancer treatment have progressed rapidly over the last few years, such that many patients now have new treatment options available to them, including immunotherapy. By activating the body’s own immune system to identify and destroy tumor cells, immunotherapies have shown significant potential and are often becoming effective treatment options for cancer care providers and their patients. However, there is still a need for ongoing research of these investigational combinations to continue the advancement of cancer treatment.
“Southern Cancer Center is proud to offer an advanced clinical research team that works closely with the National Cancer Institute, US Oncology Research and the pharmaceutical industry to explore new treatment options and bring cutting edge clinical trial opportunities to our patients,” said Dr Michael Meshad, medical research director for Southern Cancer Center. “We’re not just treating cancer, but helping patients find the most progressive and effective treatment possible.”
SCC is conducting this clinical trial through US Oncology Research, one of the largest research programs in the United States focused on oncology clinical trials. US Oncology Research has participated in about 10 studies with first-in-human therapies and 30 studies with the first U.S. or global patient enrollment.